That’s roughly how long I have to review a patient’s history, examine her, explain my diagnosis, write a prescription, and – particularly if I’m prescribing a specialty medication – walk her through ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...

GSK is planning to start a phase 3 trial of the new vaccine later this month, saying it will be the first late-stage trial of ...

Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...

Nine mid-sized pharma companies have signed up for the Trump administration's Most Favoured Nation (MFN) pricing deals, ...

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, trumpeting new data for its ...

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients ...

Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV ...

Cytokinetics has revealed the highly anticipated data from the ACACIA-HCM study of Myqorzo, which promises to take the cardiac myosin inhibitor into new territory for the class. First teased in May, ...

Through increased government investment in AI and in silico technologies, and prominent partnerships and milestones from companies like 1st Biotherapeutics, Galux, Hanmi Pharm, and LG Research AI, ...

South Korea’s mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in ...

The new acquisition is Lilly's ninth since the start of the year, coming just a few weeks after it agreed to buy psychedelic ...